Finally, RHAMM (also known as HMMR, Hyaluronan-mediated motility receptor, CD168; IHABP) is a well-characterized CML-associated leukemia antigen.21 Previous work had shown serum specificity for this antigen in 5 of 16 CML patients tested.21, 22 In this study of 19 treated CML patients with minimal residual disease, none displayed IgG reactivity to RHAMM at baseline; however, a total of 7 patients responded after vaccination (5 after primary vaccination and another 2 after secondary vaccination). This evidence concerns the gene HMMR and leukemia.